Information Provided By:
Fly News Breaks for July 31, 2019
CHMA
Jul 31, 2019 | 04:52 EDT
Piper Jaffray analyst Edward Tenthoff started Chiasma with an Overweight rating and $11 price target. The company is developing Mycapssa, the first oral therapy for acromegaly, Tenthoff tells investors in a research note. He projects global Mycapssa sales of $501M in 2028 and sees approval in mid-2020 with a U.S. launch in 2021.
News For CHMA From the Last 2 Days
There are no results for your query CHMA